Drugs that target the upregulation of the proteasome or autophagy in combination with inducers of HSP70, HSPB1, HSPB8, and DNAJ can enhance the removal of ALS-associated mutant protein aggregates, potentially improving patient survival. Here, HSPB1 is linked to amyotrophic lateral sclerosis.